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Ras GTPases regulate intracellular signaling involved
in cell proliferation. ElevatedRassignaling activity has
been associated with human cancers. Ras activation
is catalyzed by guanine nucleotide exchange factors
(GEFs), of which SOS1 is a major member that trans-
duces receptor tyrosine kinase signaling to Ras. We
have developed a rational approach coupling virtual
screening with experimental screening in identifying
small-molecule inhibitors targeting the catalytic site
of SOS1 and SOS1-regulated Ras activity. A lead
inhibitor, NSC-658497, was found to bind to SOS1,
competitively suppress SOS1-Ras interaction, and
dose-dependently inhibit SOS1 GEF activity. Muta-
genesis and structure-activity relationship studies
map the NSC-658497 site of action to the SOS1 cata-
lytic site, anddefine thechemicalmoieties in the inhib-
itor essential for the activity. NSC-658497 showed
dose-dependent efficacy in inhibiting Ras, down-
stream signaling activities, and associated cell prolif-
eration. Thesestudiesestablishaproof ofprinciple for
rational design of small-molecule inhibitors targeting
Ras GEF enzymatic activity.
INTRODUCTION
H-,N-,K-Ras are the foundingmembers of the Ras superfamily of
small GTPases, and are known to transduce signals from various
cellular receptors, including receptor tyrosine kinases, G-pro-
tein-coupled receptors, and cytokine receptors, to engage in
multiple intracellular signaling pathways leading to cell prolifera-
tion, differentiation, survival, and gene expression (Buday and
Downward, 2008; Rojas et al., 2011; Vigil et al., 2010). Gain-of-
function mutations of H-,N-, K-Ras and components of Ras
signaling (e.g., EGFR, BCR-Abl, MEK, PI3K, and AKT) have
been identified in a myriad of human cancers (Karnoub and
Weinberg, 2008; Pylayeva-Gupta et al., 2011). In addition, aber-
rant Ras signaling is involved in several developmental disor-
ders, known as the cardio-facio-cutaneous (CFC) diseases
(i.e., NF-1, Costello syndrome, and Noonan syndrome) (Cox1618 Chemistry & Biology 21, 1618–1628, December 18, 2014 ª2014and Der, 2010). Ras activity in cells is regulated by two classes
of enzymes that control its guanine-nucleotide-bound states:
the activators, guanine nucleotide exchange factors (GEFs),
that stimulate the exchange of Ras-bound GDP for GTP and
enable Ras to interact with their effectors leading to down-
stream signaling, and the inactivators, GTPase-activating pro-
teins (GAPs), that stimulate GTP hydrolysis and switch off Ras
signaling (Buday and Downward, 2008; Pierre et al., 2011; Rojas
et al., 2011; Vigil et al., 2010).
There are three subfamilies of Ras GEFs, i.e., SOS, Ras-GRF,
and Ras-GRP, that are expressed in different cell types (Rojas
et al., 2011). In particular, SOS1 is a ubiquitously expressed
multidomain enzyme with a REM domain and a Cdc25 catalytic
domain essential for Ras GTPase activation and signaling (Pierre
et al., 2011; Rojas et al., 2011). The REM and Cdc25 domains
contain two distinct sites for Ras binding: a catalytic site and
an allosteric site. The catalytic site binds GDP-bound Ras and
stimulates GDP/GTP exchange on Ras (Margarit et al., 2003;
Sondermann et al., 2004). Gain-of-function SOS1 mutations
have been identified in patients with the developmental disorder
Noonan syndrome (Roberts et al., 2007; Tartaglia et al., 2007)
and genetic disorder hereditary gingival fibromatosis type 1
(Hart et al., 2002; Jang et al., 2007), and SOS1 has been shown
to be differentially expressed in prostate and breast cancer sam-
ples (Field et al., 2012; Timofeeva et al., 2009). In addition, SOS1
has been recognized as a critical nodal mediating signal flow
from receptor tyrosine kinases to Ras and downstream ERK
and PI3K cascades.
To date, the Ras signaling module has been difficult to target;
most strategies targeting Ras signaling have been geared to-
ward downstream effectors (e.g., Raf, MEK, PI3K, and AKT) (Vigil
et al., 2010) or posttranslational modification events (e.g., farne-
syltransferases) (Appels et al., 2005; Hara et al., 1993; James
et al., 1993). In recent years, there have been several efforts
that show limited success in suppressing Ras signaling by tar-
geting either the GEF or effector binding site on Ras, and by
designing SOS1-Ras interface peptidomimetics derived from
SOS1 (Hocker et al., 2013; Patgiri et al., 2011; Scho¨pel et al.,
2013; Zimmermann et al., 2013). More recently, studies in
high-throughput screening and fragment-based screening of
chemical libraries to disrupt Ras signaling (Maurer et al., 2012;
Ostrem et al., 2013; Sun et al., 2012) have produced interesting
leads of various small molecules affecting Ras activity in cells,
including a small molecule activator of SOS1 that binds to aElsevier Ltd All rights reserved
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Rational Design of SOS1 Inhibitorspocket of SOS1, aside from the Ras catalytic pocket that poten-
tiates SOS1-mediated Ras activation (Burns et al., 2014). How-
ever, it remains to be seen if targeting of the catalytic site of
SOS1 that directly disrupts SOS1 catalysis and binding of Ras
could yield useful small molecule inhibitors, which may present
a more drug-treatable strategy in the pursuit of rational inhibition
of the crucial Ras signaling nodal.
Here we have carried out a virtual screen of small molecule in-
hibitors targeting the Ras-interactive catalytic site of SOS1,
based on structural information of the SOS1-Ras complex (Son-
dermann et al., 2004), followed by an experimental validation
in the SOS1-catalyzed Ras GEF reaction. We have identified a
class of synthetic compounds that recognize the catalytic
pocket of SOS1, and characterized them as effective inhibitors
of Ras signaling in cells. The studies establish a targeting
approach for Rasopathies that can be useful for the development
of future therapeutics.
RESULTS
Targeting the Ras Catalytic Site of SOS1 by Virtual and
Experimental Screenings
Crystal structures of the Ras-bound SOS1 complex, as well as
other resolved structures of SOS1 and its complexes, provide
structural data to guide the rational design of inhibitors of
SOS1-Ras interactions (Sondermann et al., 2004). Here, the
Ras-bound structure (Protein Data Bank [PDB] ID: 1XD2) was
used to carry out a virtual screen for chemicals targeting the
SOS1 pocket that interacts with Ras (Figure 1A). The Ras switch
II region binding site in the catalytic binding region on SOS1 (Fig-
ure 1B) contains a hydrophobic pocket formed by residues
W809, T829, H911, and K939 that appears to be suitable for
binding of a small molecule (Figure 1B). Therefore, we hypothe-
sized that there may exist small molecules that can bind in this
pocket and interfere with the interaction between SOS1 andRas.
Using a subset of 118,500 small molecules from the NCI/DTP
Open Chemical Repository, a multistage docking protocol was
adopted to identify top hits for experimental screening and vali-
dation. In the first step, a set of 30,000 candidates were selected
using a limited sampling. This set was subsequently reduced to a
set of top 3,000 hits with improved sampling, and further re-
ranked using extensive sampling in docking simulations (Figures
1C and 1D) (Biesiada et al., 2011). Top hits with relatively high
predicted binding affinity and consistent binding to a specific
site in a dominant pose within the simulation box, thus resulting
in low entropy of clustering poses obtained in multiple docking
runs, were combined and clustered by their structural similarities
(Figure 1C). This resulted in a set of 135 candidate chemicals, of
which 36 chemical compounds were selected for experimental
screening based on additional filtering involving an assessment
of drug-like properties, similarity to classes of compounds often
identified in virtual screening as false positives, and availability of
compounds from the NCI/DTP Open Chemical Repository (Fig-
ures 1C and 1D; Table S1 available online). For experimental
screening, a fluorescence-based guanine nucleotide exchange
assay utilizing a BODIPY-fluorescein (FL)-labeled GDP nucleo-
tide was refined based on previous studies (Figure S1) (Evelyn
et al., 2009; Lenzen et al., 1995, 1998; McEwen et al., 2001,
2002). The REM-Cdc25 domains of SOS1 and the H-Ras proteinChemistry & Biology 21, 1618–162with c-terminal 21 amino acid truncation were expressed as his-
tidine-tagged proteins in Escherichia coli and purified. The set of
36 compounds were initially screened at a concentration of
100 mM for their ability to inhibit SOS1-catalyzed BODIPY-FL
GDP nucleotide dissociation from H-Ras in exchange for GTP
(Figure 1D; Figure S2). Two hit compounds, NSC-674954 and
NSC-658497, as partial and complete inhibitors at 100 mM,
respectively, of SOS1-catalyzed Ras GEF reaction were identi-
fied (Figures 1E and 1F; Figure S2). The more active chemical in-
hibitor, NSC-658497, was selected for further characterizations.
Biochemical Characterization of NSC-658497 as an
Inhibitor of SOS1
To validate NSC-658497 as an inhibitor of SOS1 catalytic activ-
ity, two complementary GEF reaction assays were performed in
the presence or absence of the chemical. First, NSC-658497
was found to inhibit SOS1-catalyzed BODIPY-FL GDP nucleo-
tide dissociation from H-Ras in exchange for GTP in a dose-
dependent manner (Figure 2A). Second, NSC-658497 inhibited
SOS1-catalyzed BODIPY-Texas red (TR) GTP loading of H-Ras
dose-dependently (Figure 2B). NSC-658497 also conformed to
our prediction of disrupting the SOS1-Ras interaction in blocking
the binding of SOS1-cat to H-Ras competitively in a microscale
thermophoresis (MST) assay (Figure 2D) and a glutathione S-
transferase (GST)-tagged H-Ras pull-down assay (Figure S3A).
Direct titration of NSC-658497 to SOS1 revealed that it directly
bound to SOS1 with a low micromolar affinity (KD of 7.0 mM),
but not to H-Ras (Figure 2D; Figure S3B). To further rule out po-
tential artifacts of spectroscopic interference, UV-Vis absor-
bance spectrum of NSC-658497 (Figure S4) was measured to
confirm that NSC-658497 did not show absorption at any of
the wavelengths used for the fluorescence-based GEF or bind-
ing assays. Taken together, these biochemical results validated
that NSC-658497 is an effective SOS1 inhibitor in interfering with
SOS1-catalyzed Ras GEF reaction.
Mutagenesis of SOS1 and Structure-Activity
Relationship of NSC-658497
To map the site of action for NSC-658497, alanine scanning
mutagenesis of the SOS1 residues predicted to be involved in
binding to NSC-658497 or Ras were carried out by mutating
14 residues in the SOS1 catalytic site to alanine one at a time.
Of these 14 single-point mutants, four (I825A, T828A, T829A,
and Y912A) completely abrogated binding to NSC-658497 (Fig-
ure 3A). The lack of binding activity was not likely due to improper
protein folding as three of the mutants remained catalytically
active toward Ras (Figure S3C). The fourth mutant, T829A, was
catalytically dead, but is known to be required for interaction
with H-Ras (Boriack-Sjodin et al., 1998). Interestingly, three of
these four mutants (I825A, T828A, and T829A) mapped to a hy-
drophobic cavity in the catalytic site of SOS1 involved in Ras
switch II recognition, as predicted by computational docking
studies (Figures 3A and 3B). Two other mutants, W809A and
K814A, showed an enhanced binding to NSC-658497, likely
due to a relieved steric hindrance and creation of a deeper
pocket for accommodating NSC-658497 (Figure 3A), while
H911A and K939A displayed only a slight reduction in binding,
possibly due to being substituted by water molecules (Fig-
ure 3A). Taken together, these mutagenesis studies suggest8, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1619
Figure 1. Rational Design and Identification of Small Molecule Inhibitors of SOS1
(A) The crystal structure of H-Ras in complex with the catalytic site of SOS1 (REM andCdc25 domains) (PDB ID: 1XD2, chains C and B) (Sondermann et al., 2004).
SOS1 and Ras are depicted in green and orange, respectively. The targeted pocket on SOS1 is highlighted with magenta.
(B) The structure of SOS1 (PDB ID: 1XD2, chain C) with the amino acid residues that interact with H-Ras shown in magenta, and the residues surrounding the
H-Ras Switch II binding site labeled in white. The approximate position of the simulation box for virtual screening is indicated by the red rectangle. Both the top
and side views of the H-Ras interacting surface on SOS1 are depicted.
(C) Distribution of predicted binding affinities (defined as negative log of the median Ki obtained in multiple runs of docking simulations, and binned into intervals
on the x axis) in subsequent iterations of a multistage virtual screening protocol, as described in the Supplemental Experimental Procedures. The first, second,
and third steps of the docking protocol are indicated by the blue, red, and green histograms, respectively. The top candidate compounds were ranked using a
combination of –log(Ki) and entropy of clustering of docking poses (shown in the inset). The position of our top hit compound, NSC-658497, is indicated by a star
(*). Further filtering, as described in the Supplemental Experimental Procedures, resulted in the selection of 36 top candidate compounds for experimental testing.
(D) The overall scheme of the computational and experimental screening approach. First, 118,500 compounds from the NCI synthetic chemical collection were
docked in silico, as described in (C), against the catalytic site on SOS1. Then, 135 compounds were identified and 36 top candidate compounds were selected
and ordered from the NCI for experimental testing, as described in the flowchart and in the Supplemental Experimental Procedures. As a result of the experi-
mental dissociation assay screen at a dose of 100 mM, two hit compounds were identified.
(E) 100 mM NSC-674954 (blue) partially inhibited 50 nM SOS1-cat (red) mediated GDP/GTP nucleotide exchange upon 2 mM H-Ras (aa 1-166) (black) in the
BODIPY-FL-GDP dissociation assay.
(F) 100 mMNSC-658497 (blue) completely abrogated 50 nM SOS1-cat (red) mediated GDP/GTP nucleotide exchange upon 2 mMH-Ras (aa 1-166) (black) in the
BODIPY-FL-GDP dissociation assay.
Data in (E) and (F) are expressed as percentage change of relative fluorescence units normalized to the initial time point over 15 min. Data in (E) and (F) were
measured in triplicate and represent the mean of N = 3 experiments.
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Rational Design of SOS1 Inhibitorsthat NSC-658497 binds to the catalytic site of SOS1 involved in
interaction with the Ras switch II region (Figure 3B).
To further understand the structure-activity relationship (SAR)
of the SOS1 inhibitor, a series of structural analogs of NSC-
658497 containing the rhodanine or analogous hydantoin core
moieties were examined by the SOS1-catalyzed BODIPY-FL1620 Chemistry & Biology 21, 1618–1628, December 18, 2014 ª2014GDP dissociation guanine nucleotide exchange reaction of Ras
(Figure 4). Consistent with the mutagenesis data, alterations of
the benzopyran moiety, which maps to the hydrophobic cavity
in the catalytic site of SOS1, yielded significant changes in inhib-
itory potency. Elimination of the benzene ring while retaining the
same pyran substitutions in Compound A1 (IC50 of 10.8 mM) ledElsevier Ltd All rights reserved
Figure 2. Biochemical Validation of NSC-658497 as an Inhibitor of SOS1
(A) Dose-dependent inhibition of 50 nM SOS1-cat (black) mediated GDP/GTP nucleotide exchange upon 2 mMH-Ras (gray) in the BODIPY-FL-GDP dissociation
assay at the indicated concentrations of NSC-658497.
(B) Dose-dependent inhibition of 100 nM SOS1-cat (black) mediated GDP/GTP nucleotide exchange upon 2 mM H-Ras (gray) in the BODIPY-TR-GTP loading
assay at the indicated concentrations of NSC-658497.
(C) Label-free MST analysis of NSC-658497 direct binding to SOS1-cat. NSC-658497 was titrated between 0.01 and 350 mM to a constant amount of purified
his6-SOS1-cat (500 nM) resulting in a KD of 5.153 ± 0.076 Log M (7.04 mM).
(D) Competition of MST binding was performed in which NSC-658497 dose-dependently inhibited titration of purified his6-H-Ras (aa 1-166) (0.4–100 mM) binding
to NT-647 cysteine-labeled purified his6-SOS1-cat (50 nM) (bar graph). Data are expressed as relative binding and represent normalized binding values to the
DMSO control at a nonsaturating concentration H-Ras (12.5 mM).
Data in (A) and (B) are expressed as percentage change of relative fluorescence units normalized to the initial time point over 15 min. Data in (A) and (B) were
measured in triplicate and represent the mean of N = 3 experiments. Data in (C) and (D) represent the mean ± SEM of N = 3 experiments.
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Rational Design of SOS1 Inhibitorsto a slight increase in potency. Retention of the dicarbonyl struc-
ture lacking a ring structure, as in compound A2, caused a 3-fold
decrease in activity, while saturation of the double bond linker
completely abrogated activity, as seen in compound A3. Further-
more, replacement of the benzopyran moiety with simple phenyl
systems or removal of the benzopyran moiety (compounds B1–
B4) resulted in a complete loss of activity (Figure 4; Table S2).
The overall similar activity seen with variance of the nitrophenyl
moiety across analogs C1–C5 is consistent with attributing the
activity to the benzofuran modifications.
Alteration of the nitrophenyl group in NSC-658497, which may
interact with the polar residue Y912 in SOS1, modestly reduced
activity. Deletion of the nitro function entirely, as in Compound
C1, led to a 3-fold decrease in activity. Additions of simple hy-
droxyl (compound C2) or methoxy (compound C3) substituents
at the ortho position had no effect on the 3-fold loss of activity.
Adding both the hydroxyl and methoxy substituents, as in Com-
pound C5, at the ortho and meta positions, respectively, led to
slight improvements in activity, but did not affect the level of
NSC-658497 activity. Dimethoxy substitutions at the meta and
para positions led to further loss of activity, as seen in Compound
C4 (Figure 4; Table S1). These SAR results are consistent with the
mutagenesis data in identifying both the pyran and nitrophenyl
moieties of NSC-658497 to be preferential for binding to SOS1.Chemistry & Biology 21, 1618–162NSC-658497 Inhibits Ras Signaling and Proliferation of
Murine Fibroblasts
To assesswhether NSC-658497 is active in inhibiting Ras activity
and signaling in cells, NIH 3T3mouse fibroblast cells were serum
starved and treated with varying concentrations of NSC-658497.
Subsequently, the cells were stimulated with epidermal growth
factor (EGF) to activate the EGF receptor (EGFR)-SOS1-Ras
signaling (Buday and Downward, 2008; Pierre et al., 2011). As
shown in Figures 5A and 5B, NSC-658497 dose-dependently in-
hibitedEGF-stimulatedRas, but not EGFRactivation. Ras activa-
tion is known to signal downstream through the RAF-MEK
signaling axis (Karnoub and Weinberg, 2008; Pierre et al., 2011;
Vigil et al., 2010) to activate ERK1/2 or through the PI3K signaling
axis to activate AKT (Boulbes et al., 2010; Jacinto et al., 2006;
Karnoub and Weinberg, 2008; Vigil et al., 2010). Concomitant
to Ras inhibition, NSC-658497 dose-dependently inhibited the
EGF-activated, Ras downstream targets ERK1/2 and AKT (Fig-
ure 5B). NSC-658497 appears to be selective for SOS1-Ras
signaling as it did not affect H-Ras-related R-Ras activity (Fig-
ure 5A), known to be independent of EGF-SOS1 signaling (Buday
and Downward, 2008; Ohba et al., 2000; Tian and Feig, 2001).
Additionally, NSC-658497 did not affect activity of the more
distantly related Rho GTPase, Rac1, in cells (Figure S5A), further
supporting the selectivity of NSC-658497.8, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1621
Figure 3. Mapping the Site of Action on
SOS1 for NSC-658497
(A) Identification of the site of action of NSC-
658497 on SOS1-cat through mutagenesis
studies. (Right) Single alanine mutants of both the
catalytic and allosteric sites of SOS1-cat were
generated, as described in the Supplemental
Experimental Procedures. MST analysis of NSC-
658497 direct binding to SOS1-cat was per-
formed. NSC-658497 was titrated between 0.006
and 100 mM to a constant amount of NT-647
amine-labeled purified his6-SOS1-cat (100 nM).
Dissociation constants (KD) were determined by
nonlinear regression, as described in the Experi-
mental Procedures, and expressed as a bar
graph. Key interacting residues are indicated by
the red, blue, and magenta boxes on the bar
graph. (Left) A structural view of the site of action
for NSC-658497 in the catalytic site of SOS1. Key
residues in SOS1 that interact with NSC-658497
based on the mutagenesis studies are labeled in
white and highlighted in red, blue, or magenta.
(B) A structural depiction of the interaction of the
switch II region of H-Ras bound to the docking
pocket of NSC-658497 in the catalytic site of SOS1
(left). In silicodockingmodelofNSC-658497bound
to the catalytic site of SOS1 based on docking
simulations, mutagenesis, and SAR data (right).
Data in (A) are expressed as a bar graph of relative
binding affinities normalized to the binding affinity
of WT SOS1-cat. In (A), if KD was unable to be
determined due to lack of a binding event, data
are expressed as 0 in the bar graph. Data in (A)
represent the mean ± SEM of N = 3 experiments.
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Rational Design of SOS1 InhibitorsThe Ras-MEK-ERK1/2 and Ras-PI3K-AKT signaling axes are
critical for cell proliferation (Karnoub and Weinberg, 2008; Pierre
et al., 2011; Vigil et al., 2010). NSC-658497 dose-dependently in-
hibited cell proliferation in parallel with its inhibitory activity for
the Ras downstream targets ERK1/2 and AKT in both NIH 3T3
fibroblasts and HeLa cells (Figures 5C and 5D; Figure S5B).
Additionally, the effect of NSC-658497 appeared reversible in
inhibiting downstream ERK1/2 activity (Figure S5C). To examine
the specificity of NSC-658497 in suppressing SOS1-Ras
signaling, mouse embryonic fibroblasts overexpressing an
active H-Ras mutant (G12V) known to be GTP-hydrolysis defi-
cient and able to signal independently of SOS1-mediated Ras
activation (Pylayeva-Gupta et al., 2011) were generated (Stengel
and Zheng, 2012). While NSC-658497 inhibited Ras signaling
and proliferation of wild-type (WT) MEF cells in a dose-depen-
dent manner (Figures 5E and 5F), it did not affect the proliferation
or signaling of the H-Ras mutant cells (Figures 5G and 5H).
Consistent with these results, NSC-658497 dose-dependently
suppressed Ras signaling mediated by the overexpression of
an active SOS1 mutant (W729L), originally identified in Noonan
syndrome (Tartaglia et al., 2007), in human embryonic kidney
cells (Figure S5D). Taken together, these results suggest that
NSC-658497 is specific for SOS1-Ras-mediated cell functions.
NSC-658497 Inhibits Ras Signaling and Proliferation of
Cancer Cells
SOS1 has been shown to be differentially expressed in prostate
and breast cancer patient populations (Field et al., 2012; Timo-1622 Chemistry & Biology 21, 1618–1628, December 18, 2014 ª2014feeva et al., 2009) and is required for Ras signaling and cell prolif-
eration of prostate cancer cells (Timofeeva et al., 2009). We next
tested the ability of NSC-658497 to inhibit DU-145andPC-3 pros-
tate cancer cell proliferation and Ras signaling. As shown in Fig-
ure 6, NSC-658497 dose-dependently inhibited Ras-GTP activity
and the downstream p-ERK1/2 and p-Akt activities, aswell as the
proliferation, of these cells, similar to that by a SOS1-specific
siRNA knockdown approach (Timofeeva et al., 2009).
As a component of the NCI chemical library, NSC-658497
has been tested in the NCI-60 DTP human tumor cell line screen
(http://dtp.nci.nih.gov). The DTP/NCI database shows that NSC-
658497 was most sensitive on HOP-92 non-small-cell lung can-
cer cells and OVCAR-3 ovarian cancer cells comparing with
A549 non-small-cell lung cancer and OVCAR-5 ovarian cancer
cells, respectively (Figure S5E). Interestingly, the HOP-92 and
OVCAR-3 cells contain WT K-Ras status, while the A549 and
OVCAR-5 cells contain oncogenic K-Ras mutations. These re-
sults are consistent with the MEF cell data, suggesting a selec-
tivity of NSC-658497 in inhibiting the growth of cells bearing
WT Ras versus oncogenic mutant Ras (Figure 5C). NSC-
658497 could be useful for selectively inhibiting the proliferation
of prostate, lung, and ovarian cancer cells that show elevated
Ras activity but do not contain oncogenic Ras mutations.
DISCUSSION
Exploration for small molecule inhibitors of protein-protein inter-
actions to dissect cell-signaling pathways and as leads forElsevier Ltd All rights reserved
Figure 4. SAR Study of NSC-658497 Struc-
tural Analogs
NSC-658497 and related structural analogs were
tested for their ability to dose-dependently inhibit
50 nM SOS1-cat mediated GDP/GTP nucleotide
exchange upon 2 mM H-Ras (aa 1-166) in the
BODIPY-FL-GDP dissociation assay.
(Bottom) IC50s are depicted in the table and were
calculated based on a single time point of 900 s
and nonlinear regression analysis (Prism 6;
GraphPad).
(Top) The NSC-658497 analogs were grouped
into three groups (A, B, and C) based on their
chemical structure, as depicted in the schematic.
IC50 values represent the mean ± SEM of N = 3
experiments.
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Rational Design of SOS1 Inhibitorstherapeutic development has become increasingly attractive
(Bosco et al., 2012). Multiple strategies can be employed to
identify such candidate inhibitors, including nonbiased high-
throughput screening or structure based in silico screening (Eve-
lyn et al., 2009; Evelyn et al., 2007; Gao et al., 2004). In recent
years, there has been a renewed effort at targeting Ras GTPases
that were once considered untreatable with drugs. In particular,
Rac and Rho inhibitors, NSC-23766 and Rhosin, were identified
to target the GEF interactive pockets in the small GTPase Rac1
and RhoA, respectively (Gao et al., 2004; Shang et al., 2012). InChemistry & Biology 21, 1618–1628, December 18, 2014 ªrelated studies, fragment-based high-
throughput screening has been used to
identify chemical fragments of small mol-
ecules that bind to the GEF interaction
surface of K-Ras, and, as a conse-
quence, disrupt SOS-mediated Ras
signaling (Maurer et al., 2012; Sun et al.,
2012). In addition, several recent studies
targeting oncogenic K-Ras GEF and
effector binding have been carried out
using high-throughput screening and
fragment-based screening of cysteine-
modifying small molecule fragments,
respectively (Ostrem et al., 2013; Zim-
mermann et al., 2013). Intriguingly, one
such study yielded a small molecule acti-
vator, not inhibitor, of Ras activity in vitro
(Burns et al., 2014). It should be noted,
however, that this class of small mole-
cules appears to inhibit, rather than acti-
vate, Ras downstream signaling events
in cells (Burns et al., 2014). Another study
used a SOS1-derived peptide to disrupt
SOS1-Ras interaction and subsequent
Ras signaling, but its utility in cells re-
mains unclear (Patgiri et al., 2011).
Conceptually, the activator enzymes,
i.e., GEFs, of small GTPases repre-
sent attractive targets in manipulating
their substrates, Ras GTPases, activities
because they typically contain deeper,
more drug-treatable catalytic pocketsthat are critical for maintaining the activities of individual Ras
family members. Our recent studies in rational targeting of Rho
GEFs by small molecule inhibitors have provided an experi-
mental basis for pursuing inhibitors with a similar mode of action
against Ras GEF (Shang et al., 2013). In the present work, struc-
tural information on SOS1 and its complexes (Sondermann et al.,
2004) serve as starting points to perform a virtual screen using
the NCI chemical library. We selected a hydrophobic cavity
and nearby polar residues in the SOS1 catalytic domain that
form an oblong bowl for Ras binding as the target for small2014 Elsevier Ltd All rights reserved 1623
Figure 5. NSC-658497 Inhibits Ras
Signaling and Proliferation of Mouse Fibro-
blast Cells
(A and B) NIH/3T3 cells were serum starved
overnight and pretreated with the indicated con-
centrations of NSC-658497 for 2 hr. Subsequently,
the cells were stimulated with 50 ng/ml of EGF
for 5 min and were subjected to GST-Raf1 effector
domain pull-down experiments or downstream
Ras signaling western blotting experiments.
The activation of pan-Ras and R-Ras, along with
the activation of phospho-ERK1/2, phospho-AKT,
and phospho-EGFR were analyzed by western
blotting, as described in the Supplemental
Experimental Procedures.
(C) NIH/3T3 cells were grown in the presence
of DMSO or indicated concentrations of NSC-
658497 over 3 days. Every 24 hr the proliferation of
the NIH/3T3 cells were measured by MTS assay,
as described in the Experimental Procedures.
(D, E, and G) After overnight starvation and 2 hr
pretreatment with the indicated concentrations of
NSC-658497, cells were subjected to downstream
Ras signalingwesternblotting for phospho-ERK1/2
and phospho-AKT activation, as described in the
Supplemental Experimental Procedures. WT MEF
cells (E) and H-RasG12V transduced MEF cells (G)
were subjected to a 2-day proliferation assay. MEF
cells were grown in the presence of DMSO or indi-
cated concentrations of NSC-658497 for 2 days.
Then, proliferationwasmeasuredbyMTSassay, as
described in the Experimental Procedures.
(F and H) WT-MEF and H-RasG12V-MEF cells
were serum starved overnight, and then treated
with the indicated concentrations of NSC-658497
for 2 hr. After compound treatment, the cells were
subjected to phospho-ERK1/2 and phospho-AKT
activation western blotting, as described in the
Supplemental Experimental Procedures.
Data in (A), (B), and (D) are representative of N = 3
experiments. Data in (C) were measured in tripli-
cate and represent themean ±SEM.Data in (C) are
plotted as fold change in growth using Day 0 as the
baseline. Data in (E) and (G) were performed in
triplicate and represent the mean ± SEM. Data in
(E) and (G) are plotted as fold change in growth
using Day 0 as the baseline. Data in (F) and (H) are
representative of N = 3 experiments. Statistical t
test analyses were performed using GraphPad
Prism 6 on data in (E) (10 mM NSC-658497: p
value=0.039; 20mMNSC-658497: p value=0.047;
40 mM NSC-658497: p value = 0.011).
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Multistage virtual screening against this site generated a short
list of potential candidates that were subjected to a subsequent
low-throughput experimental screening using the GEF reaction
assay. As a result, a lead chemical inhibitor of SOS1GEF activity,
NSC-658497, was identified.
Biochemical analysis of this lead compound confirmed that it
bound to SOS1 directly with a binding constant in the micro-
molar range, and it can competitively interfere with the SOS1-
Ras interaction. Subsequent mutagenesis mapping and SAR
analysis of the NSC-658497 structure indicated that the site of
action in SOS1 likely included the hydrophobic residue I8251624 Chemistry & Biology 21, 1618–1628, December 18, 2014 ª2014and the surrounding polar Y912 and T829 residues that are
critical for binding to the switch II region of Ras, whereas the
aromatic benzopyran and the polar nitrophenyl moieties of
NSC-658497 were critically involved in the inhibitory activity.
Given its hydrophobicity, the benzopyran moiety may bind to
the hydrophobic pocket of the SOS1 site, thus serving as an an-
chor within the catalytic site of SOS1, while the polar nitrophenyl
moiety may be involved in interactions outside of the hydro-
phobic core of the SOS1 site. Future cocrystal studies of the
lead inhibitor-SOS1 complex hopefully will corroborate with
these experimental data. Additionally, since most key residues
identified in the SOS1 site of action are conserved in SOS2Elsevier Ltd All rights reserved
Figure 6. NSC-658497 Inhibits Ras
Signaling and Proliferation of Prostate
Cancer Cells
(A and C) DU-145 and PC-3 prostate cancer cells
were subjected to a 3-day proliferation assay. PC-
3 and DU-145 cells were grown in the presence of
DMSO or the indicated concentrations of NSC-
658497 for 3 days. Every 24 hr proliferation was
measured by MTS assay, as described in the
Experimental Procedures.
(B and D) DU-145 and PC-3 cells were serum-
starved overnight, and then treated with the
indicated concentrations of NSC-658497 for 2 hr.
GST-Raf1 effector domain pull-down experi-
ments for pan-Ras and downstream Ras signaling
western blot experiments for phospho-ERK1/2
and phospho-AKT activation were performed
as described in the Supplemental Experimental
Procedures.
Data in (A) and (C) were performed in triplicate and
represent the mean ± SEM. Data in (A) and (C) are
plotted as relative growth by normalizing the data
to Day 0. Data in (B) and (D) are representative of
N = 3 experiments.
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SOS isoforms. Conversely, because the key residues in the
targeted pocket of SOS1 are not well conserved in the other
Ras GEFs, i.e., RasGRF1 and RasGRP1 (Figures S6B–S6D), it
is possible that NSC-658497 does not work on these Ras acti-
vators. These predictions will need further experimental testing
to verify their accuracy.
In cells, NSC-658497 showed a dose-dependent inhibition of
H-Ras activation through the well-established EGF-SOS1-Ras
cascade, but not the EGF-SOS1 signaling independent R-Ras
activity (Buday and Downward, 2008; Ohba et al., 2000; Tian
and Feig, 2001). It potently suppressed the Ras downstream
p-ERK and p-Akt activities and the associated cell prolifera-
tion without affecting upstream EGFR signaling or active mutant
Ras-driven cell signaling. The inhibitory activity was not
restricted to fibroblasts, as the inhibitor was equally functional
in HeLa cells and prostate cancer cells. Interestingly, NSC-
658497 mimicked the effects of SOS1 knockdown in the pros-
tate DU-145 cells where SOS1 is overexpressed and dominant
in supporting Ras activity and cell growth (Timofeeva et al.,
2009). Among the cancer cell lines tested in the NCI repository
(http://dtp.nci.nih.gov), NSC-658497 appeared to show a selec-
tive inhibition of growth of lung and ovarian cancer cells bearing
WT K-Ras alleles, not the oncogenic K-Ras-activating muta-
tions, suggesting that SOS1 is a potential target for patient
groups with cancers overexpressing SOS1 as a biomarker.
Additionally, there has been increasing interest in targeting
oncogenic Ras in active K-Ras mutant-driven cancers. Recent
studies suggest that SOS1 may play a role in oncogenic
K-Ras tumorigenesis in pancreatic, colon, and breast
cancer models dependent on WT H- and N-Ras through an au-
tocrine loop (Grabocka et al., 2014; Hocker et al., 2013; JengChemistry & Biology 21, 1618–1628, December 18, 2014 ªet al., 2012). It will be interesting to
see if the SOS1 inhibitor could also
have an advantage in targeting onco-genic K-Ras-driven tumors both in in vitro cell and in vivo
mouse models, or whether the SOS1-H-/N-Ras-dependent pro-
liferation of K-Ras-driven tumors is limited to certain cancer
types.
In summary, we have employed structural information and a
functional biochemical GEF reaction assay to rationally design
and identify a lead class of small molecule inhibitors of the
RasGEF, SOS1. Our studies of the lead inhibitor, NSC-658497,
establish an approach of rational targeting of Rasopathies that
Ras-activating enzymes, such as SOS1, may serve as useful
targets for future development of anticancer therapeutics.
SIGNIFICANCE
Ras GTPases are well-known regulators of cell growth and
survival activities critical for the development and progres-
sion of multiple human cancers. The activators of Ras,
RasGEFs, are attractive targets in Ras pathway-driven tu-
mors due to their potential drug treatability as enzymes
catalyzing the Ras activation reaction. This study uses
structural information of a key RasGEF, SOS1, to perform a
virtual screen to identify small molecule inhibitors that sup-
press SOS1-catalyzed Ras activation and disrupt the SOS1-
Ras interaction. Our lead small molecule inhibitor identified
in this study binds to the catalytic site on SOS1 with a low
micromolar affinity. Additionally, our lead small molecule
inhibitor suppresses Ras activation and downstream
signaling in cells, alongwith preventing the growth of cancer
cells dependent on Ras activity. We present an approach of
targeting Rasopathies and a class of small molecule inhibi-
tors of SOS1 useful as both biological tools and for future
therapeutic development.2014 Elsevier Ltd All rights reserved 1625
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Plasmids, Cell Lines, and Reagents
Details for plasmid generation, cell lines used, and reagents used are
described in the Supplemental Experimental Procedures.
Computational Virtual Screening and SAR Analysis
Virtual screening was performed to identify candidate molecules that could
disrupt the interaction between SOS1 and H-Ras, by targeting the SOS1 inter-
action interface with H-Ras (catalytic site). The docking simulations for the vir-
tual screening were performed as described in the Supplemental Experimental
Procedures using a subset of 118,500 drug-like synthetic compounds from the
NCI/DTP Open Chemical Repository (http://dtp.cancer.gov).
Protein Purifications
Details for protein purifications are given in the Supplemental Experimental
Procedures.
MST Binding Assays
MST is a biophysical technique that measures the motion of molecules
along microscopic temperature gradients. Fluorescent-labeled molecules or
intrinsic fluorescence of molecules are used to monitor their movement along
these temperature gradients. Changes in a molecule’s hydration shell, charge,
or size affects a molecule’s movement along these temperature gradients.
These changes are used to determine binding events (Wienken et al., 2010).
For label-free analysis, 500 nM his6-SOS1-cat was incubated with indicated
concentrations of NSC-658497 in binding buffer (20 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, 0.1% Tween-20, and 3.5% DMSO) at room
temperature for 30 min. Subsequently, samples were loaded into hydrophilic
capillaries (NanoTemper Technologies) and binding was measured with a
Monolith NT.Label Free reader (NanoTemper Technologies) based on intrinsic
tryptophan fluorescence of the SOS1-cat protein.
For labeled analysis, both purified his6-SOS1-cat (WT and mutant) and
C-terminal truncated his6-H-Ras were labeled with the red NT-647 amine-
reactive dye using N-hydroxy succinimide-ester chemistry using a protein-
labeling kit (NanoTemper Technologies). Indicated concentrations of NSC-
658497 were incubated with NT-647-labeled SOS1cat (100 nM) or H-Ras
(100 nM) in binding buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
MgCl2, 0.1% Triton X-100, and 2% DMSO) at room temperature in the dark
for 30 min. For competition binding experiments, purified his6-SOS1-cat was
labeled with the red NT-647 cysteine-reactive dye using a protein-labeling
kit (NanoTemper Technologies). Indicated concentrations of purified his6-H-
Ras (aa 1-166) were incubated with NT-647-labeled SOS1-cat (50 nM) in the
presence of indicated concentrations of NSC-658497 in binding buffer
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM MgCl2, 0.1% Tween-20, and
2%DMSO) at room temperature in the dark for 30min. Subsequently, samples
were loaded into hydrophilic capillaries (NanoTemper Technologies) and bind-
ing wasmeasuredwith aMonolith NT.115 reader (NanoTemper Technologies).
Binding data were analyzed using thermophoresis or hot/cold analysis, as
described previously (Jerabek-Willemsen et al., 2011). Data were normalized
to either DFnorm[%] (10*(Fnorm(bound) – Fnorm(unbound))) or fraction bound
(DFnorm[%]/amplitude) (Jerabek-Willemsen et al., 2011). Dissociation con-
stants (KD) of the binding data were calculated using nonlinear regression anal-
ysis (Prism 6; GraphPad).
Western Blot Analysis
Details for the western blot analysis are given in the Supplemental Experi-
mental Procedures.
Guanine Nucleotide Exchange Reaction Assays
For the GDP dissociation assay, purified his6-H-Ras (aa 1-166) was preloaded
with BODIPY-FL-GDP for 1 hr at room temperature (stoichiometric ratio of 4
protein:1 labeled nucleotide). Exchange buffer (EB) (20 mM Tris-HCl [pH
7.5], 150 mM NaCl, 1 mM MgCl2, 0.01% NP-40 Alternative, 1 mM DTT) was
added to wells of a 96-well plate (3915; Corning) for both the GDP-dissociation
and GTP-loading assays. Also for the GDP-dissociation and GTP-loading as-
says, 82 and 85 ml of EB were added to wells containing H-Ras alone respec-
tively, and 73 and 76 ml of EB were added to wells containing both H-Ras and1626 Chemistry & Biology 21, 1618–1628, December 18, 2014 ª2014SOS1-cat, respectively. For both assays, 9 ml of purified his6-SOS1-cat (50 nM
in GDP-dissociation assay and 100 nM in GTP-loading assay) were added to
appropriate wells. For the GDP-dissociation assay, 10 ml of 50-fold excess
of GTP (100 mM final) were added to each well. Subsequently, in both assays,
DMSO and indicated concentrations of NSC-658497 were added to the wells
(1% DMSO in final concentration), and the plate was shaken for 30 s and incu-
bated for 10 min at room temperature. In the GDP-dissociation assay, 8 ml of
his6-H-Ras (aa 1-166) bound to BODIPY-FL-GDP (2 mM final concentration)
were added to each well. In the GTP-loading assay, 2.5-fold excess
BODIPY-TR-GTP (5 mM final concentration) was added to each well.
The plates were read continuously for 15 min on an EnVision plate reader
(PerkinElmer) with the excitation at 485 nm and emission at 535 nm in the
GDP-dissociation assay, and the excitation at 560 nm and emission at
635 nm in the GTP-loading assay.
MTS Cell Proliferation Assay
The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium, inner salt (MTS) cell proliferation assay was carried
out per the manufacturer’s instructions (G3580; Promega) starting with
2,000 cells (H-Ras-G12V MEF cells) or 1,000 cells (WT MEF, NIH/3T3, HeLa,
DU-145, or PC-3 cells) per well, in triplicate per sample. Briefly, 100 ml cell sus-
pension aliquots containing 2,000 cells or 1,000 cells were added to every well
of a 96-well plate (Corning) and cultured 24 hr. Then, cells were treated with
indicated concentrations of NSC-658497 or DMSO for 24, 48, or 72 hr. Subse-
quently, the medium was changed to 100 ml of complete DMEM medium plus
20 ml of MTS substrate (Promega). The metabolic activity of the cells was
analyzed by absorbance change at 490 nm with a VMax Kinetic ELISA micro-
plate reader (Molecular Devices) after a 2 hr incubation at 37C and 5% CO2.
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